Retraction Watch

Weekend reads: ‘A lab in recovery’; ‘my paper was proved wrong’; a journal apologizes

Would you consider a donation to support Weekend Reads, and our daily work?

The week at Retraction Watch featured:

After saying it would retract an article, Cureus changed its mind
Former Columbia University psychiatrist committed research misconduct, says federal watchdog
Exclusive: Cancer researchers in Iran under investigation as questions swirl around dozens of studies
Retractions begin for chemist found to have faked data in 42 papers
A journal switches to a new publisher, then corrects a paper. What should happen to the old version?

Our list of retracted or withdrawn COVID-19 papers is up past 400. There are more than 50,000 retractions in The Retraction Watch Database — which is now part of Crossref. The Retraction Watch Hijacked Journal Checker now contains more than 250 titles. And have you seen our leaderboard of authors with the most retractions lately — or our list of top 10 most highly cited retracted papers? What about The Retraction Watch Mass Resignations List — or our list of nearly 100 papers with evidence they were written by ChatGPT?

Here’s what was happening elsewhere (some of these items may be paywalled, metered access, or require free registration to read):

A journal switches to a new publisher, then corrects a paper. What should happen to the old version?

In January 2022, The Oncologist switched publishers from Wiley to Oxford University Press.

Last month, the journal issued an extensive correction for one of its most popular articles, a 2020 paper that describes results of a clinical trial the authors claimed found a homeopathic intervention improved quality of life and survival for people with advanced lung cancer.

The article page that remains on Wiley’s website, however, does not reflect the recent correction.

Retractions begin for chemist found to have faked data in 42 papers

A nanotube researcher in Japan has earned 13 retractions, with more to come, after an extensive investigation by the country’s National Institute of Advanced Industrial Science and Technology (AIST) revealed widespread misconduct in his work.

AIST’s investigation found Naohiro Kameta, senior principal researcher at the Nanomaterials Research Institute located in AIST’s Ibaraki campus, fabricated and falsified dozens of studies. He was apparently dismissed from his role following the findings.

The institute first learned of the problems in Kameta’s work in November 2022, according to a translated version of the investigation report. Initially, they looked into five papers, but eventually expanded their scrutiny to 61 articles on which Kameta was the lead or responsible author.

Exclusive: Cancer researchers in Iran under investigation as questions swirl around dozens of studies

Year after year, a husband-and-wife team at a university in Iran has been publishing studies involving research on cell lines ostensibly purchased from the Pasteur Institute of Iran, in Tehran.

But the couple may never have been in possession of the cells. In correspondence obtained by Retraction Watch, the Pasteur Institute told their employer, Jahrom University of Medical Sciences, only three of the many cell lines described in their publications had been available at the national cell bank over the past decade.

A university official confirmed the two researchers – Fraidoon Kavoosi, an associate professor in the department of anatomical science, and his wife Masumeh Sanaei, an assistant professor in the same department – were under investigation.

Former Columbia University psychiatrist committed research misconduct, says federal watchdog

A psychiatry researcher who received a warning letter from the U.S. Food and Drug Administration earlier this year committed research misconduct, another federal watchdog found.

Bret Rutherford, formerly a research psychiatrist at the New York State Psychiatric Institute and Columbia University, “engaged in research misconduct by recklessly falsely reporting that all human research subjects met the inclusion/exclusion criteria for late-life depression studies,” according to a case summary from the U.S. Office of Research Integrity (ORI) published today.

As The Transmitter previously reported, a suicide that occurred during one of Rutherford’s trials in 2021 was followed by a suspension of his research a few months later. The U.S. Office of Human Research Protections subsequently halted all federally funded research involving human participants at the institute in June 2023 and launched a review of its research practices.

After saying it would retract an article, Cureus changed its mind

Karen Rech, a hematopathologist at Mayo Clinic in Rochester, Minn., was reading a case report about a rare disease when she recognized the patient.

Although the authors of the paper were affiliated with the University of North Dakota School of Medicine and Health Sciences in Fargo, the patient in the report had gone to Mayo for care, and Rech had made the pathology diagnosis. But the article, “A Diagnostic Dilemma and Classification Conundrum: Atypical Histiocytic Neoplasm Presenting as a Calvarial Mass,” published in Cureus in February, didn’t mention or credit Rech or her colleagues.

“The ability to make such a unique diagnosis is a direct result of my translational research in histiocytic neoplasms,” Rech wrote in an email to the journal in April. After she made the pathology diagnosis, a hematologist colleague saw the patient, and a group of specialists discussed the case and came to a consensus diagnosis.

Weekend reads: Retractions by Nobel Prize winners; privatizing peer review; fake mouse brains

Would you consider a donation to support Weekend Reads, and our daily work?

The week at Retraction Watch featured:

Here’s what was happening elsewhere (some of these items may be paywalled, metered access, or require free registration to read):

Authors sue Sage over “discriminatory” retractions of papers cited in abortion pill case

The authors of three papers about abortion Sage retracted earlier this year have sued the publisher, alleging the company pulled the articles “for pretextual and discriminatory reasons.”

In February, Sage retracted three articles from Health Services Research and Managerial Epidemiology “because of undeclared conflicts of interest and after expert reviewers found that the studies demonstrate a lack of scientific rigor that invalidates or renders unreliable the authors’ conclusions,” according to the publisher’s statement at the time. Sage also removed the paper’s lead author from the editorial board of the journal.

A federal judge cited two of the articles last year in his decision to suspend approval of mifepristone, a drug used in medical abortions.

Pain researcher in Italy up to seven retractions

A physiatrist in Italy has lost four publications this year after two groups of researchers raised concerns about his research.

The physician, Marco Monticone, a professor at the University of Cagliari, had three papers pulled in 2022, as we reported at the time. Those retractions followed a critique by Cochrane researchers who analyzed data in 10 randomized controlled trials (RCTs) headed by Monticone.

Neil O’Connell, of Brunel University of London, lead author of the critique, told us:

New engineering dean has two retractions for authorship manipulation

A newly appointed dean at the University of Guelph in Canada has had two papers retracted for “evidence of authorship manipulation.”

Another article by the researcher, Moncef Nehdi, formerly of McMaster University in Hamilton, Ontario, seems to match a paper that had its authorship advertised for sale, according to a post on PubPeer.

Nehdi told Retraction Watch he stands by his group’s work in the two retracted papers, but agreed with the retractions because he thought the investigations “raised some valid concerns.”

Nehdi began a five-year term as dean of the University of Guelph’s College of Engineering and Physical Sciences on September 1, according to an announcement this spring. The announcement stated:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this:

Share this: